Updates in ESR1-Mutant Breast Cancer | Supplements And Featured Publications

Parsing Out Remaining Questions With CDK4/6 Inhibitors in HR+ Breast Cancer

January 05, 2021

Sarah Sammons, MD, discusses the clinical significance of ESR1 mutations in HR-positive, HER2-negative breast cancer, how to determine the optimal timing to perform genetic sequencing for ESR1 mutations, and emerging agents, like lasofoxifene, that are poised to transform the paradigm for patients who harbor these mutations.

Overcoming CDK4/6 Inhibitor Resistance in ESR1-Mutant HR+/HER2- Breast Cancer

December 17, 2020

Massimo Cristofanilli, MD, highlights the introduction of CDK4/6 inhibitors, such as abemaciclib, ribociclib, and palbociclib, which has been a significant addition to the hormone receptor–positive, HER2-negative breast cancer armamentarium.

x